propranolol has been researched along with Combat Disorders in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Combat Disorders: Neurotic reactions to unusual, severe, or overwhelming military stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Posttraumatic stress disorder (PTSD) may involve over-consolidated emotional memories of the traumatic event." | 2.80 | Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies. ( Fischer, AM; Goetz, JM; Lasko, NB; Marin, MF; Orr, SP; Pitman, RK; Rosasco, ML; Spring, JD; Suris, AM; Wood, NE, 2015) |
| "Post-traumatic stress disorder (PTSD) is increasingly recognized as a serious and potentially debilitating condition in combat veterans returning from Iraq and Afghanistan." | 2.47 | Novel combination strategy to optimize treatment for PTSD. ( North, CS; Shad, MU; Suris, AM, 2011) |
| "The propranolol failed to produce any measurable effects on acquisition or retention of the CR and there was no evidence of increased conditionability in individuals diagnosed with PTSD." | 1.33 | Effects of beta blockade, PTSD diagnosis, and explicit threat on the extinction and retention of an aversively conditioned response. ( Gilbertson, MW; Lasko, NB; Metzger, LJ; Milad, MR; Orr, SP; Pitman, RK, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wood, NE | 1 |
| Rosasco, ML | 1 |
| Suris, AM | 2 |
| Spring, JD | 1 |
| Marin, MF | 1 |
| Lasko, NB | 2 |
| Goetz, JM | 1 |
| Fischer, AM | 1 |
| Orr, SP | 2 |
| Pitman, RK | 2 |
| Cukor, J | 1 |
| Spitalnick, J | 1 |
| Difede, J | 1 |
| Rizzo, A | 1 |
| Rothbaum, BO | 1 |
| Shad, MU | 1 |
| North, CS | 1 |
| Milad, MR | 1 |
| Metzger, LJ | 1 |
| Gilbertson, MW | 1 |
| Paquette, M | 1 |
| Lohmöller, G | 1 |
| Lydtin, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol[NCT00709735] | Phase 4 | 23 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Developing Memory Reconsolidation Blockers as Novel PTSD Treatments[NCT01490697] | Phase 4 | 34 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD[NCT04468360] | Phase 2 | 256 participants (Anticipated) | Interventional | 2022-03-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses during script-driven imagery of traumatic combat events that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator and left lateral frontalis facial muscle electromyogram (EMG) responses in microVolts. Responses for the two traumatic scripts were averaged and square-root transformed for analysis. Responses during personal traumatic imagery of previously studied individuals with and without current PTSD was used to calculate each participant's posterior probability of being classified as PTSD. (NCT00709735)
Timeframe: Day 8
| Intervention | percent probability (Mean) |
|---|---|
| Non-Reactivation Propranolol (NRP) | 32 |
| Reactivation Propranolol (RP) | 45 |
IES-R is a 22-item patient reported measure of PTSD symptoms. Each question is answered using a 5-point scale where 0=not at all to 4=extremely for a total possible score of 0 to 88. Lower scores represent less severe symptoms and higher scores representing more severe symptoms. IES-R change scores were calculated by subtracting the Day 2 IES-R total score from the Day 8 IES-R total score. A negative change from Baseline indicates improvement of symptoms and a positive change from Baseline indicates a worsening of symptoms. (NCT00709735)
Timeframe: Day 2 (Baseline ) and Day 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 8 | |
| Non-Reactivation Propranolol (NRP) | 43.3 | -8.2 |
| Reactivation Propranolol (RP) | 45.0 | 4.5 |
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses to script-driven imagery of traumatic events that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator electromyogram (EMG) responses of the left lateral frontalis facial muscle in microVolts. Responses for the traumatic scripts were averaged and square-root transformed for analysis. Responses during personal traumatic imagery of previously studied individuals with and without current PTSD was used to calculate each participant's posterior probability of being classified as PTSD. (NCT01490697)
Timeframe: 1 week following treatment (Day 14)
| Intervention | percent probability (Mean) |
|---|---|
| Placebo Plus Placebo | 44 |
| Mifepristone Plus d-Cycloserine (DCS) | 45 |
IES-R is a 22-item patient reported measure of PTSD symptoms. Each question is answered using a 5-point scale where 0=not at all to 4=extremely for a total possible score of 0 to 88. Lower scores represent less severe symptoms and higher scores representing more severe symptoms. IES-R change scores were calculated by subtracting the Day 14 IES-R total score from the Day 7 IES-R total score. A negative change from Baseline indicates improvement of symptoms and a positive change from Baseline indicates a worsening of symptoms. (NCT01490697)
Timeframe: Day 7 (Baseline) and Day 14
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 14 | |
| Mifepristone Plus d-Cycloserine (DCS) | 52.4 | -8.9 |
| Placebo Plus Placebo | 55.3 | -5.0 |
2 reviews available for propranolol and Combat Disorders
| Article | Year |
|---|---|
Emerging treatments for PTSD.
Topics: Cognitive Behavioral Therapy; Combat Disorders; Computer Simulation; Cycloserine; Humans; Implosive | 2009 |
Novel combination strategy to optimize treatment for PTSD.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Combat Disorders; Dru | 2011 |
1 trial available for propranolol and Combat Disorders
| Article | Year |
|---|---|
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.
Topics: Adrenergic beta-Antagonists; Adult; Arousal; Combat Disorders; Double-Blind Method; Emotions; Female | 2015 |
3 other studies available for propranolol and Combat Disorders
| Article | Year |
|---|---|
Effects of beta blockade, PTSD diagnosis, and explicit threat on the extinction and retention of an aversively conditioned response.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arousal; Association Learning; Combat Disorders; Condition | 2006 |
Healing trauma: finding treatments that work.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Anxiety Agents; Combat Disorders; Ev | 2007 |
[Hyperkinetic heart syndrome].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output; Combat Disorders; Diagnosis, Differenti | 1971 |